Swiss clinical-stage biotechnology company LimmaTech Biologics AG has entered into a definitive agreement to be acquired by Lilly in a transaction valued at up to $780 million in cash. The deal includes an upfront payment as well as additional potential payments tied to clinical and regulatory milestones. Announced in Schlieren, near Zurich, on May 26, 2026, the agreement highlights growing pharmaceutical interest in vaccines that can prevent serious bacterial infections before treatment becomes necessary.
A Focus on Hard-to-Prevent Bacterial Disease
LimmaTech is developing vaccine candidates for bacterial pathogens that remain difficult to prevent and are increasingly challenging to treat because of rising antimicrobial resistance. Its work targets infections caused by Staphylococcus aureus, Neisseria gonorrhoeae, and Chlamydia trachomatis, all of which can lead to significant medical complications. The company’s approach is built around a self-adjuvating, multi-antigen vaccine platform designed to generate broad and durable immune responses against complex bacterial threats.
Lead Program Targets Surgical-Site Infections
The company’s lead candidate, LTB-SA7, is currently in Phase 1 development as a vaccine against Staphylococcus aureus. S. aureus is widely recognized as a major cause of surgical-site infections, making it a high-priority target for prevention in hospital and surgical settings. Rather than focusing primarily on bacterial surface antigens, LimmaTech’s platform is designed to address toxins and superantigens that contribute to disease severity.
Pipeline Extends to Women’s Health-Related Infections
Beyond its Staphylococcus aureus program, LimmaTech is advancing preclinical vaccine candidates against gonorrhea and chlamydia. These infections can cause long-term consequences, including infertility, and their burden often falls disproportionately on women. By pursuing preventive vaccines for pathogens with limited or weakening treatment options, the company aims to change the trajectory of diseases that are becoming harder to manage with antibiotics alone.
Strategic Fit for Lilly
LimmaTech Chief Executive Officer Franz-Werner Haas said the acquisition represents a significant next phase for the company’s science and team. He noted that Lilly’s global development capabilities, manufacturing scale, and commitment to serious disease could help accelerate LimmaTech’s Staphylococcus aureus vaccine and support progress across its earlier-stage gonorrhea and chlamydia programs. Lilly’s leadership also emphasized the public health importance of preventing bacterial infections as antimicrobial resistance reduces the effectiveness of existing therapies.
Transaction and Advisory Support
Under the agreement, Lilly will acquire LimmaTech for total potential cash consideration of up to $780 million, including both the upfront component and milestone-based payments. LimmaTech’s board leadership described the transaction as recognition of the value built by the company, its investors, and its technology platform. Moelis & Company UK LLP is serving as financial adviser to LimmaTech, while Goodwin Procter and Vischer are acting as legal advisers.
The planned acquisition positions LimmaTech’s vaccine platform within a larger global pharmaceutical organization with the resources to advance clinical development and manufacturing. For Lilly, the deal expands its exposure to next-generation vaccine science at a time when bacterial infections and antimicrobial resistance are creating urgent unmet needs. If successfully developed, LimmaTech’s programs could contribute to a prevention-led strategy for infections that currently impose significant clinical and public health burdens.